Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfaf165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obinutuzumab for PLA2R-associated membranous nephropathy.
Nephrol Dial Transplant
August 2025
Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial.
Drug Des Devel Ther
July 2025
Department of Medicine, Division of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010050, China.
Background: Membranous nephropathy (MN) can cause nephrotic syndrome. B cells contribute to MN, but available treatments are often inadequate. We addressed this treatment gap by analyzing the effect of obinutuzumab in patients with primary MN (PMN).
View Article and Find Full Text PDFAdditive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.
Am J Nephrol
May 2025
Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Introduction: Rituximab has become the first-line therapy for patients with membranous nephropathy (MN). However, approximately 30-40% of patients with MN do not respond to rituximab. We presented our single-center experience of treating rituximab-refractory MN with obinutuzumab which is a humanized and glycoengineered type II anti-CD20 monoclonal antibody.
View Article and Find Full Text PDFObinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.
Clin Kidney J
May 2025
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Background: Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy.
Methods: A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart.
Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.
J Nephrol
February 2025
Department of Nephrology, The Alfred Hospital, Melbourne, VIC, Australia.
Background: Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults, with high risk of progression to end-stage kidney disease when untreated. Rituximab is commonly used in its treatment however many patients do not respond. Obinutuzumab is a novel anti-CD20 monoclonal antibody for which there is increasing observational evidence in treatment-resistant membranous nephropathy.
View Article and Find Full Text PDF